Dossier assessment
Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)
Report documents
-
Extract of dossier assessment
Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)
-
Dossier assessment
Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)
Dossier assessment
Vitreomacular traction, including when associated with macular hole of diameter ≤ 400 microns
Added benefit not proven for mild or severe symptoms
Additional information
Federal Joint Committee (G-BA)
2019-04-04 A G-BA decision was published.
Project details
- Project no.
- A18-68
- Commission
- Commission awarded on 12.10.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-01-15.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68
Status: Commission completed
-
Dossier assessment
Ocriplasmin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed